RET and medullary thyroid gland carcinoma: Efficacy and toxicity of selpercatinib compared to the standard of care (i.e. cabozantinib or vandetanib) for the treatment of advanced/metastatic progressive RET-mutant MTC, naive to any prior MKIs therapy, have been recently investigated in the phase III clinical trial LIBRETTO-531 (ClinicalTrials.gov no. NCT04211337) (4).